Download PDF
Zeitschrift für Orthomolekulare Medizin 2015; 4(04): 16-19
DOI: 10.1055/s-0035-1547592
Wissen
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Kokosöl fürs Gehirn

Ulrike Gonder
Further Information

Publication History

Publication Date:
27 January 2016 (online)

    Permissions and Reprints

Zusammenfassung

Die meist früh in der Pathogenese einer Alzheimerdemenz auftretenden Störungen im Zucker- und Insulinstoffwechsel führen zu einem Energiedefizit im Gehirn. In Kasuistiken deutet sich an, dass MCT-reiches Kokosöl eine ideale Ergänzung in der Ernährung von Patienten mit milden Demenzformen und in der Prophylaxe ist, da die enthaltenen Fettsäuren bevorzugt in Ketone umgewandelt werden, die das Defizit ausgleichen können.

Schlüsselwörter

Alzheimer - Demenz - FINGER-Studie - Insulinresistenz - Energieversorgung von Neuronen - Ketonkörper - Neuroprotektion - Kokosöl - MCT-Fette
 

  • Literatur

  • 1 Bredesen DE. Reversal of cognitive decline: a novel therapeutic program. Aging 2014; 6: 707-717
    Google Scholar
  • 2 Brookmeyer R et al. Projections of Alzheimer’s Disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342
    CrossrefPubMedGoogle Scholar
  • 3 Ngandu T et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255-2263
    CrossrefGoogle Scholar
  • 4 Parletta N et al. Nutritional modulation of cognitive function and mental health. J Nutr Biochem 2013; 24: 725-743
    CrossrefGoogle Scholar
  • 5 Cunnane S et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 2011; 27: 3-20
    CrossrefGoogle Scholar
  • 6 De la, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 2005; 7: 45-61
    Google Scholar
  • 7 Yao J et al. Shift in brain metabolism in late onset Alzheimer’s disease: implications for biomarkers and therapeutic interventions. Mol Asp Med 2011; 32: 247-257
    CrossrefGoogle Scholar
  • 8 Hu T et al. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: A meta-analysis of randomized controlled clinical trials. Am J epidemiol 2012; 176: S44-S54
    CrossrefGoogle Scholar
  • 9 Schwingshackl L, Hoffmann G. Long-term effects of low glycemic index/load vs. high glycemic index/load diets on parameters of obesity and obesity-associated risks: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 2013; 23: 699-706
    CrossrefGoogle Scholar
  • 10 Buyken AE et al. Carbohydrate nutrition and inflammatory disease mortality in older adults. Am J Clin Nutr 2010; 92: 634-643
    CrossrefGoogle Scholar
  • 11 Castellano CA et al. In contrast to lower brain glucose uptake, brain ketone uptake is unchanged in mild Alzheimer’s disease: A dual tracer PET study comparing 18F-FDG and 11C-acetoacetate. Hot topic oral presentation. Clin Trials Alzheimer’s Dis. San Diego: 2013
    Google Scholar
  • 12 Laeger T et al. Role of β-hydroxybutyric acid in the central regulation of energy balance. Appetite 2010; 54: 450-455
    CrossrefGoogle Scholar
  • 13 Paoli A et al. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr 2013; 67: 789-796
    CrossrefGoogle Scholar
  • 14 Kossoff EH et al. Ketogenic Diets: Treatments for Epilepsy and Other Disorders. New York: Demos Health; 2011
    Google Scholar
  • 15 Noh HS et al. Acetoacetate protects neuronal cells from oxidative glutamate toxicity. J Neurosci Res 2006; 83: 702-709
    CrossrefGoogle Scholar
  • 16 Kashiwaya Y et al. D-β-Hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc Natl Acad Sci USA 2000; 97: 5440-5444
    CrossrefGoogle Scholar
  • 17 Maynard SD, Gelblum J. Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate Alzheimer’s disease. Neuropsychiatr Dis Treat 2013; 9: 1619-1627
    Google Scholar
  • 18 Newport MT et al. A new way to produce hyperketonemia: Use of ketone ester in a case of Alzheimer’s disease. Alzheimers Dement 2015; 11: 99-103
    CrossrefGoogle Scholar
  • 19 Henderson ST et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab 2009; 6: 31
    CrossrefGoogle Scholar
  • 20 Krikorian R et al. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging 2012; 33: 425.e19-425.e27
    CrossrefGoogle Scholar
  • 21 Reger M et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004; 25: 311-314
    CrossrefGoogle Scholar
  • 22 Bergen S et al. Hyperketonemia induced in man by medium-chain triglyceride. Diabetes 1966; 15: 723-725
    CrossrefGoogle Scholar
  • 23 Fernando WMADB et al. The role of dietary coconut for the prevention and treatment of Alzheimer’s disease: potential mechanism of action. Brit J Nutrition 2015; 114: 1-14
    CrossrefGoogle Scholar
  • 24 Couchesne-Loyer A et al. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: Estimated potential contribution to brain energy metabolism. Nutrition 2013; 29: 635-640
    CrossrefGoogle Scholar
  • 25 Newport M. Alzheimer vorbeugen und behandeln. Die Keton-Kur: Wie ein natürliches Fett die Erkrankung aufhält Kirchzarten: VAK; 2012
    Google Scholar